UNSPSC 51282916: Enrofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DX3XEK1BN, chemically known as 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid but generally known as enrofloxacin, which bears US NIH Compound Identifier 71188. European Medicines Agency schedules Enrofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06550MIG.

UNSPSC 51282916 Enrofloxacin, a Commodity code, shows limited recent state and local procurement activity aligned with its pharmaceutical scope. The two most recent opportunities tagged to this code involve pharmaceutical products—one a completed piggybacked warehouse contract for fluoroquinolone and tetracycline antibiotics, and the other a county procurement for naloxone and drug deactivation systems—neither of which directly corresponds to enrofloxacin procurement. The code nominally covers enrofloxacin, a veterinary fluoroquinolone antibiotic used primarily in animal health applications, but state and local solicitations under this code do not appear to reflect routine enrofloxacin purchasing at scale.

The Illinois Department of Public Health awarded a $2,999,999.11 contract through the MMCAP Infuse cooperative purchasing consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets under Invitation for Bid (IFB), with an initial 12-month term and two renewal options. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though the response deadline stated in the summary (July 26, 2023) appears inconsistent with the posting date. State and local procurement under this code appears driven by opportunistic cooperative purchasing vehicles and episodic county health initiatives rather than standing demand for enrofloxacin products themselves. The geographic activity reflected is limited to Illinois and Florida, with no broad regional pattern evident from the available data. Business development professionals should verify whether enrofloxacin-specific opportunities are actually reaching the market under this code or whether related veterinary pharmaceutical codes may be more productive avenues for pursuit.